ChromaDex
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.
In 2011, Dartmouth College announced it granted ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside which it markets and sells as an ingredient under the brand name Tru Niagen. The firm also offers contract research services for sourcing raw materials, identifying new compounds, and developing processes for large scale manufacturing. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound trademarked as pTeroPure via the company's BluScience product line. ChromaDex no longer sells PteroPure.
Elysium Health bought the ingredients in its "Basis" product from ChromaDex. The two firms had an agreement under which Elysium didn't have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the head of manufacturing from ChromaDex and stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.
